MedTrace Logo

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

NCT01954251 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 829

Last updated 2018-05-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess immunogenicity, reactogenicity and safety of GSK Biologicals' HZ/su vaccine when its first dose is co-administered with the FLU-D-QIV vaccine in adults aged 50 years or older compared to administration of vaccines separately.

Conditions

  • Herpes Zoster

Interventions

BIOLOGICAL

Herpes Zoster vaccine GSK 1437173A

2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.

BIOLOGICAL

GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A

2 doses administered intramuscularly (IM) in the deltoid region of the dominant arm.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-10-03
Primary Completion
2014-06-02
Completion
2015-03-20

Countries

  • United States
  • Canada
  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01954251 on ClinicalTrials.gov